NEOG News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

NE

Mkt Cap

$2.68B

Volume

1.73M

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neogen Corporation - NEOGThe FDA issued a warning letter to Neogen Corporation on September 29, 2026, following an investigation linking its veterinary wound care product Neogen Vet HYCOAT to at least 20 horse deaths from serious infections. The contaminated sterile solution represents the largest number of horse deaths associated with a quality defect in an FDA-regulated veterinary product. Neogen initiated a voluntary recall in January 2026. The announcement triggered a 7.22% stock price decline. Pomerantz LLP is investigating potential securities fraud claims on behalf of investors.GlobeNewswire Inc. · Oct 13, 2026

Zacks Industry Outlook Highlights ICU Medical, Neogen and Trulieve CannabisThe Medical Products industry faces moderate growth prospects with resilient healthcare demand offset by tariff pressures and manufacturing costs. ICU Medical shows strong momentum in infusion systems with improving earnings, Neogen benefits from commercial execution improvements in food and animal safety, while Trulieve Cannabis expects growth acceleration from new markets like Georgia and Texas despite Florida seasonal softness.Zacks Investment Research · Oct 12, 2026

Compared to Estimates, Neogen (NEOG) Q1 Earnings: A Look at Key MetricsNeogen reported Q1 2026 revenue of $222.8 million, up 6.5% year-over-year, beating the consensus estimate of $208.09 million by 7.07%. EPS came in at $0.08 versus the estimate of $0.05, representing a 60% surprise. The company showed strong performance across most segments, with Food Safety revenue at $163.2 million and Animal Safety at $59.6 million, both exceeding analyst expectations. The stock has a Zacks Rank #2 (Buy) rating.Zacks Investment Research · Oct 6, 2026

Neogen (NEOG) Q1 Earnings and Revenues Beat EstimatesNeogen reported quarterly earnings of $0.08 per share, beating consensus estimates of $0.05 and marking a 60% earnings surprise. The company also exceeded revenue expectations with $222.8 million, up from $209.19 million year-over-year. Despite strong performance, Neogen's Medical-Products industry ranks in the bottom 35% of Zacks industries. The stock has gained 86.1% year-to-date and holds a Zacks Rank #2 (Buy) rating.Zacks Investment Research · Oct 6, 2026

Neogen Stock Rallies 83% YTD: What's Driving the Surge?Neogen (NEOG) shares have surged 83% year-to-date, outperforming the S&P 500, driven by strong Food Safety segment growth with core revenue increases of 5.8% in Q4 fiscal 2026. The company is expanding manufacturing capabilities following its 3M Food Safety acquisition, planning a 50% increase in R&D spending for fiscal 2027 focused on pathogen detection and sanitation platforms. However, fiscal 2027 EPS is projected to decline 3.1% before recovering with 17.2% growth in fiscal 2028.Zacks Investment Research · Oct 1, 2026

PBH vs. NEOG: Which Stock Is the Better Value Option?A comparison of two Medical-Products stocks reveals that Prestige Consumer Healthcare (PBH) offers superior value compared to Neogen (NEOG). While both companies share a Zacks Rank #2 (Buy) rating with improving earnings outlooks, PBH demonstrates significantly better valuation metrics with a forward P/E of 10.26 versus NEOG's 41.51, a PEG ratio of 1.47 versus 4.15, and a Value grade of A versus D.Zacks Investment Research · Sep 30, 2026

Veterinary Diagnostics Market Size to Soar to USD 30.78 Billion by 2035 at a CAGR of 10.1% - SNS InsiderThe global veterinary diagnostics market is projected to grow from USD 11.76 billion in 2025 to USD 30.78 billion by 2035, driven by increasing pet ownership, zoonotic disease surveillance, and advancements in point-of-care testing and molecular diagnostics. North America leads with 39% market share, while Asia-Pacific shows the fastest growth. Reagents & kits dominate products, while companion animals represent 61% of the market.GlobeNewswire Inc. · Sep 28, 2026

Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss, Tops Revenue EstimatesKestra Medical Technologies reported a Q1 loss of $0.75 per share, missing EPS expectations of $0.61 by 22.95%, though it exceeded revenue estimates with $30.97 million (6.66% above consensus). The company has underperformed the S&P 500 by 25.7% year-to-date and carries a Zacks Rank #3 (Hold) rating, with mixed estimate revisions ahead.Zacks Investment Research · Sep 14, 2026

Neogen Surges 102.8% in a Year: What's Driving the Rally?Neogen Corporation (NEOG) has demonstrated strong performance with shares rising 102.8% over the past year, outperforming the industry. The company's Food Safety division achieved its highest quarterly core growth rate since fiscal 2023 at 5.8%, while planning a 50% increase in fiscal 2027 R&D spending focused on innovation and pathogen detection. However, the company faces headwinds from foreign currency exposure affecting 51.2% of revenues and intense competition from larger corporations.Zacks Investment Research · Aug 31, 2026

Why Neogen Stock Blasted More Than 31% Higher TodayNeogen stock surged over 31% after posting a beat-and-raise fiscal Q2 earnings report. Despite revenue declining nearly 3% year-over-year to $224.7 million and net income dropping slightly, the company crushed analyst expectations and raised full-year guidance. However, the analyst expresses caution about the stock's future, noting the revenue decline and suggesting investors may be overexcited about the results.The Motley Fool · Jan 9, 2026

NE

NEOGNeogen Corp

NEOG

Pay with—

Available Balance0.00

Your PositionYou don't own any NEOG yet.

Related Tickers

Earnings